scholarly journals 329TiP KATE3: A phase III study of trastuzumab emtansine (T-DM1) in combination with atezolizumab or placebo in patients with previously treated HER2-positive and PD-L1–positive locally advanced or metastatic breast cancer

2021 ◽  
Vol 32 ◽  
pp. S509
Author(s):  
S. Loi ◽  
A. Schneeweiss ◽  
E. Song ◽  
M. Harries ◽  
M. De Laurentiis ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Locally Advanced ◽  
Metastatic Breast ◽  
Phase Iii ◽  
Trastuzumab Emtansine ◽  
Her2 Positive ◽  
Phase Iii Study ◽  
Previously Treated

Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. LBA1-LBA1 ◽  
Author(s):  
Kimberly L. Blackwell ◽  
David Miles ◽  
Luca Gianni ◽  
Ian E Krop ◽  
Manfred Welslau ◽  
...  
Keyword(s):  
Locally Advanced ◽  
Metastatic Breast ◽  
Phase Iii ◽  
Trastuzumab Emtansine ◽  
Her2 Positive ◽  
Daily News ◽  
Online Supplement ◽  
Phase Iii Study ◽  
Previously Treated ◽  
Final Text

LBA1 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Sunday, June 3, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Sunday edition of ASCO Daily News.

Sign in / Sign up

Export Citation Format

Share Document